Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

11.93
+0.21501.84%
Volume:1.99M
Turnover:24.21M
Market Cap:1.67B
PE:-3.56
High:12.42
Open:11.90
Low:11.79
Close:11.71
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:1.35
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.29
PE(LYR):-3.13

Loading ...

Intellia CFO Edward J. Dulac III Disposes of 4,677 Common Shares Valued at $84,186

Reuters
·
Jul 07

Intellia Grants 53,250 Inducement Rsus to 13 New Hires Under 2024 Plan

Reuters
·
Jul 07

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 07

Intellia Therapeutics rises 10.7%

TIPRANKS
·
Jun 17

Intellia Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jun 17

Small U.S. Stocks End Mixed As Intellia Therapeutics Leads, Bandwidth Cl A Lags

Dow Jones
·
Jun 16

Intellia Therapeutics Shares Climb Following Positive Phase 3 Results

Dow Jones
·
Jun 16

Wedbush Remains a Hold on Intellia Therapeutics (NTLA)

TIPRANKS
·
Jun 15

Intellia says Phase 3 HAELO trial shows 87% attack reduction with lonvo-z in hereditary angioedema

Reuters
·
Jun 15

Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO)

TIPRANKS
·
Jun 15

Intellia Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 15

Analysts’ Top Healthcare Picks: Intellia Therapeutics (NTLA), Electrocore (ECOR)

TIPRANKS
·
Jun 15

Intellia Therapeutics presents additional results from Phase 3 HAELO trial

TIPRANKS
·
Jun 15

Intellia reports Phase 3 trial shows lonvo-z cuts hereditary angioedema attacks 87% vs placebo

Reuters
·
Jun 13

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (Lonvo-Z) in Patients With Hereditary Angioedema

THOMSON REUTERS
·
Jun 13

Intellia Therapeutics - Initiates Rolling Bla Submission for Lonvo-Z; U.S. Launch Expected First Half 2027

THOMSON REUTERS
·
Jun 13

Intellia Therapeutics - Haleo Met Its Primary Endpoint With an 87% Reduction (P<0.0001) in Mean Monthly Attacks in Lonvo-Z Arm

THOMSON REUTERS
·
Jun 13

Intellia Therapeutics shareholders elect Class I directors at annual meeting

Reuters
·
Jun 11

A Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity Raise

Simply Wall St.
·
Jun 10

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 06